Jyothy Labs Limited has scheduled a one-on-one investor meeting with Nalanda Capital. The session is set for September 23, 2026, providing the fund house with an opportunity to engage directly with company representatives.

Meeting Details

The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the interaction.

The schedule remains subject to change based on exigencies from either party. Interested stakeholders can access the latest investor presentation on the company’s website.

Shreyas Trivedi, Head – Legal & Company Secretary at Jyothy Labs Limited, issued the intimation on September 15, 2026.

Nalanda India Equity Fund Limited increased its stake in Jyothy Laboratories to 7.60% following an open market acquisition. The fund purchased 3,102,384 shares on September 2, 2026, raising its total holding from 6.76%.

The transaction was executed via the exchange, with settlement completed on September 3, 2026. The disclosure was filed with the Bombay Stock Exchange on September 10, 2026.

Acquisition Details

The acquirer is not part of the promoter group. The purchase was made through open market transactions rather than off-market deals or preferential allotments.

Regulatory Context

The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Jyothy Laboratories Limited has a total equity share capital of 367,214,511 shares. This figure remained unchanged after the acquisition, indicating no new issuance of shares occurred during this period.

No encumbrances, pledges, or voting rights other than those attached to equity shares were reported for the acquired stake. The total diluted share capital also stands at 367,214,511 shares.